Article in The Lancet. Respiratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
2 authors.
A Scott McCallDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Veterans Affairs Medical Center, Nashville, TN, USA.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Veterans Affairs Medical Center, Nashville, TN, USA; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA. Electronic address: jon.kropski@vumc.org.
Funding
Project 4: Defining the Molecular Natural History of Early and Progressive Pulmonary FibrosisP01HL172729 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Andrew Kropski · 2024 to 2026
$11.2M
Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
Spatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0M
Mechanisms of epithelial repair and remodeling in pulmonary fibrosisR01HL153246 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2024
$2.8M
Thromboxane Receptor Signaling in Pulmonary FibrosisR01HL151016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2023
$2.1M
Mechanisms of alveolar homeostasis and repair.I01BX006121 · VA · VETERANS HEALTH ADMINISTRATION · PI KROPSKI, JONATHAN ANDREW · 2024 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Biomarker-defined endotypes of pulmonary fibrosis. · full record | OpenQuestion